|
Significant steatosis (> 33% of hepatocytes)
|
|---|
|
Test
|
APRI
|
M-APRI
|
FIB-4
|
M-FIB-4
|
B-AST
|
|---|
|
AUROC (95% CI)
|
0.837 (0.657–0.945)
|
0.923 (0.820–0.999)
|
0.683 (0.488–0.840)
|
0.942 (0.792–0.994)
|
0.942 (0.792–0.994)
|
|
Cut-off
|
0.656
|
0.577
|
0.216
|
0.179
|
92.82
|
|
Sensitivity (95% CI)
|
75 (19.4–99.4)
|
100 (39.8–100)
|
75 (19.4–99.4)
|
100 (39.8–100)
|
100 (39.8–100)
|
|
Specificity (95% CI)
|
88.46 (69.8–97.6)
|
92.3 (74.9–99.1)
|
73.1 (52.2–88.4)
|
88.46 (69.8–97.6)
|
92.3 (74.9–99.1)
|
|
+ PV
|
50.0 (23.1–76.9)
|
66.7 (34.6–88.3)
|
30.0 (15.5–50.0)
|
57.1 (31.5–79.4)
|
66.7 (34.6–88.3)
|
|
- PV
|
95.8 (80.7–99.2)
|
100
|
95.0 (77.4–99.1)
|
100
|
100
|
-
APRI aspartate-to-platelet ratio index, FIB-4 Fibrosis-4 index, M-APRI modified aspartate-to-platelet ratio index (BMI z-score x APRI), M-FIB-4 modified Fibrosis-4 index (BMI z-score x FIB-4), B-AST BMI z-score x AST, AUROC area under the receiver operating characteristic, 95% CI 95% confidence interval, + PV positive predictive value, − PV negative predictive value
